SourceBio International plc
(“SourceBio”, the “Company” or the “Group”)
COVID-19 testing contract for elite rugby in England
SourceBio testing the England Rugby squad as part of the Six Nations tournament
RFU testing services to cover Gallagher Premiership Rugby and Greene King IPA Championship testing
SourceBio International plc (AIM: SBI), the international provider of integrated state-of-the-art laboratory services and products, announces that it has entered into an agreement with the Rugby Football Union (“RFU”) and Premiership Rugby Limited to provide COVID-19 screening testing services for elite rugby in England.
Under the agreement SourceBio will provide COVID-19 testing services to England Rugby Senior Men’s squad and support staff and to all 12 Premiership Rugby clubs players and staff. In addition, the RFU is also looking to roll-out this testing service to RFU Championship clubs who will be able to use this agreement to access the services provided by SourceBio.
SourceBio will provide COVID-19 testing to players and staff around training schedules and ahead of match days. Third party healthcare professionals sourced by SourceBio will take swabs from individuals and samples are then couriered to the Company’s ISO 15189 accredited laboratory facility in Nottingham for PCR Testing. Test results are turned around in less than 24 hours.
SourceBio has processed more than 1,000,000 COVID-19 antigen RT-PCR tests for the DHSC and the NHS, Private Hospital Groups and Commercial customers since first offering its service in May 2020.
Jay LeCoque, Executive Chairman, commented: “We are very pleased to support elite rugby return to play protocols using our state-of-the-art laboratories to allow elite rugby in England to continue to safely operate within current social distancing measures. We have been at the forefront of COVID-19 testing programmes since the beginning of the pandemic, supporting the NHS and private healthcare groups, but also helping many of our commercial clients to maintain a safe working environment and helping businesses to get back on track.”
|SourceBio International plc|
|Jay LeCoque, Executive Chairman||
Via Walbrook PR
|Tony Ratcliffe, Chief Financial Officer|
|Liberum (Nominated Adviser and Broker)||
Tel: 020 3100 2000
|Walbrook PR Limited||
Tel: 020 7933 8780 or email@example.com
|Paul McManus / Sam Allen||
Mob: 07980 541 893 / 07748 651 727
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
- Infectious Disease Testing – a range of COVID-19 testing services for the Department of Health and Social Care (DHSC), the NHS, Private Healthcare groups and Commercial enterprises. Utilising various technologies (RT-qPCR, LamPore and LAMP) SourceBio offers both screening and gold standard COVID-19 testing and operates under the ISO: 15189 accreditation required by the DHSC for COVID-19 test services. SourceBio offers employee testing solutions to industry, home testing kits (including ‘Fit to Fly’ and ‘Test to Release’ approved tests) and operates Mobile Testing Unit laboratories to support event and venue testing.
- Healthcare Diagnostics – histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- Genomics – DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
- Stability Storage – shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market of the London Stock Exchange.